Concepts (203)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoma, Kaposi | 4 | 2023 | 370 | 1.020 |
Why?
|
| Papillomavirus Infections | 7 | 2022 | 1585 | 0.910 |
Why?
|
| Papillomavirus Vaccines | 4 | 2022 | 489 | 0.810 |
Why?
|
| Clinical Trials Data Monitoring Committees | 1 | 2019 | 25 | 0.700 |
Why?
|
| HIV Infections | 29 | 2023 | 16678 | 0.690 |
Why?
|
| Hepatitis B | 4 | 2023 | 695 | 0.640 |
Why?
|
| Antiviral Agents | 9 | 2017 | 2978 | 0.560 |
Why?
|
| Research Design | 2 | 2022 | 5979 | 0.500 |
Why?
|
| Endpoint Determination | 4 | 2019 | 600 | 0.490 |
Why?
|
| HIV-1 | 10 | 2022 | 6934 | 0.490 |
Why?
|
| Antiretroviral Therapy, Highly Active | 4 | 2020 | 1872 | 0.480 |
Why?
|
| Models, Statistical | 4 | 2022 | 5100 | 0.440 |
Why?
|
| Hepatitis C, Chronic | 6 | 2018 | 1027 | 0.430 |
Why?
|
| Ribavirin | 7 | 2017 | 395 | 0.430 |
Why?
|
| Hepatitis C | 6 | 2017 | 1582 | 0.410 |
Why?
|
| Hepatitis B Vaccines | 4 | 2023 | 194 | 0.370 |
Why?
|
| Markov Chains | 3 | 2008 | 969 | 0.330 |
Why?
|
| Viral Hepatitis Vaccines | 1 | 2008 | 80 | 0.310 |
Why?
|
| HIV Seropositivity | 1 | 2012 | 970 | 0.270 |
Why?
|
| Hepacivirus | 6 | 2017 | 1372 | 0.250 |
Why?
|
| Human papillomavirus 16 | 1 | 2006 | 262 | 0.240 |
Why?
|
| Data Interpretation, Statistical | 2 | 2022 | 2714 | 0.240 |
Why?
|
| Etoposide | 3 | 2023 | 637 | 0.240 |
Why?
|
| CD4 Lymphocyte Count | 6 | 2020 | 2557 | 0.230 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 2 | 2020 | 66 | 0.220 |
Why?
|
| Antibodies, Viral | 6 | 2022 | 3164 | 0.220 |
Why?
|
| Hepatitis B virus | 2 | 2023 | 513 | 0.220 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2006 | 2011 | 0.220 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2006 | 385 | 0.210 |
Why?
|
| Biometry | 1 | 2004 | 558 | 0.200 |
Why?
|
| Antibody Formation | 3 | 2022 | 1402 | 0.180 |
Why?
|
| Papillomaviridae | 2 | 2014 | 1118 | 0.180 |
Why?
|
| DNA, Viral | 2 | 2018 | 2224 | 0.180 |
Why?
|
| Viral Vaccines | 1 | 2004 | 636 | 0.170 |
Why?
|
| Interferon-alpha | 4 | 2016 | 895 | 0.170 |
Why?
|
| Hepatitis A Vaccines | 1 | 2017 | 29 | 0.160 |
Why?
|
| Lamivudine | 2 | 2022 | 342 | 0.160 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2020 | 623 | 0.160 |
Why?
|
| Hepatitis B, Chronic | 1 | 2022 | 393 | 0.150 |
Why?
|
| Uridine Monophosphate | 1 | 2017 | 69 | 0.150 |
Why?
|
| Tetanus Toxoid | 1 | 2017 | 193 | 0.150 |
Why?
|
| Immunologic Factors | 2 | 2016 | 1575 | 0.140 |
Why?
|
| Fluorenes | 1 | 2017 | 159 | 0.140 |
Why?
|
| Lipase | 1 | 2018 | 315 | 0.140 |
Why?
|
| Interferons | 2 | 2016 | 704 | 0.130 |
Why?
|
| Anal Canal | 1 | 2018 | 376 | 0.130 |
Why?
|
| Chloroquine | 1 | 2016 | 280 | 0.120 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2018 | 654 | 0.120 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2023 | 2231 | 0.120 |
Why?
|
| Cervix Uteri | 1 | 2018 | 591 | 0.120 |
Why?
|
| Monocytes | 2 | 2016 | 2593 | 0.120 |
Why?
|
| Hepatitis B e Antigens | 1 | 2014 | 133 | 0.120 |
Why?
|
| Immunologic Memory | 2 | 2018 | 1348 | 0.110 |
Why?
|
| Phenylenediamines | 1 | 2013 | 90 | 0.110 |
Why?
|
| Adjuvants, Immunologic | 3 | 2023 | 1000 | 0.110 |
Why?
|
| Consensus | 1 | 2022 | 2935 | 0.110 |
Why?
|
| Benzimidazoles | 1 | 2017 | 848 | 0.110 |
Why?
|
| HIV Envelope Protein gp120 | 3 | 2001 | 952 | 0.100 |
Why?
|
| Bone Remodeling | 1 | 2015 | 575 | 0.100 |
Why?
|
| Hepatitis B Antibodies | 3 | 2023 | 159 | 0.100 |
Why?
|
| Immunity, Humoral | 1 | 2016 | 596 | 0.100 |
Why?
|
| Hepatitis B Surface Antigens | 2 | 2023 | 305 | 0.100 |
Why?
|
| Ritonavir | 1 | 2013 | 322 | 0.100 |
Why?
|
| Adult | 23 | 2022 | 213712 | 0.100 |
Why?
|
| Viral Load | 4 | 2014 | 3292 | 0.100 |
Why?
|
| Female | 31 | 2022 | 379592 | 0.090 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2011 | 902 | 0.090 |
Why?
|
| Thiazoles | 2 | 2016 | 1484 | 0.090 |
Why?
|
| Deoxycytidine | 1 | 2014 | 824 | 0.090 |
Why?
|
| AIDS Vaccines | 3 | 2001 | 938 | 0.090 |
Why?
|
| Humans | 38 | 2023 | 742088 | 0.090 |
Why?
|
| Immunity, Cellular | 1 | 2016 | 1606 | 0.090 |
Why?
|
| Disease Progression | 3 | 2020 | 13256 | 0.090 |
Why?
|
| South America | 2 | 2020 | 181 | 0.090 |
Why?
|
| Adenine | 1 | 2014 | 936 | 0.080 |
Why?
|
| Vaginal Smears | 1 | 2012 | 511 | 0.080 |
Why?
|
| Inflammation Mediators | 1 | 2017 | 1889 | 0.080 |
Why?
|
| Pregnancy Complications, Infectious | 4 | 2008 | 2026 | 0.080 |
Why?
|
| Retrospective Studies | 7 | 2022 | 77098 | 0.080 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2016 | 1835 | 0.080 |
Why?
|
| Middle Aged | 18 | 2022 | 213127 | 0.070 |
Why?
|
| Africa South of the Sahara | 2 | 2020 | 724 | 0.070 |
Why?
|
| Voluntary Programs | 1 | 2006 | 42 | 0.070 |
Why?
|
| Male | 23 | 2022 | 349538 | 0.070 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2016 | 4379 | 0.070 |
Why?
|
| HIV Protease Inhibitors | 1 | 2008 | 430 | 0.060 |
Why?
|
| Zidovudine | 1 | 2007 | 620 | 0.060 |
Why?
|
| HIV | 3 | 2023 | 1600 | 0.060 |
Why?
|
| Cytokines | 3 | 2017 | 7317 | 0.060 |
Why?
|
| Nitro Compounds | 2 | 2016 | 75 | 0.060 |
Why?
|
| Clinical Trials as Topic | 3 | 2006 | 7901 | 0.060 |
Why?
|
| AIDS Serodiagnosis | 1 | 2006 | 184 | 0.060 |
Why?
|
| Anti-HIV Agents | 1 | 2020 | 4250 | 0.060 |
Why?
|
| Sulfonamides | 1 | 2013 | 1932 | 0.060 |
Why?
|
| Pilot Projects | 4 | 2013 | 8297 | 0.060 |
Why?
|
| Vaccines, Synthetic | 3 | 2001 | 633 | 0.060 |
Why?
|
| Viruses | 1 | 2007 | 374 | 0.060 |
Why?
|
| Gene Expression Profiling | 2 | 2016 | 9410 | 0.060 |
Why?
|
| Likelihood Functions | 1 | 2006 | 1003 | 0.050 |
Why?
|
| DNA, Mitochondrial | 1 | 2008 | 814 | 0.050 |
Why?
|
| Drug Evaluation | 1 | 2004 | 637 | 0.050 |
Why?
|
| Treatment Refusal | 1 | 2006 | 416 | 0.050 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2023 | 212 | 0.050 |
Why?
|
| Logistic Models | 2 | 2014 | 13403 | 0.050 |
Why?
|
| Mitochondrial Proteins | 1 | 2008 | 995 | 0.050 |
Why?
|
| Membrane Proteins | 1 | 2018 | 7873 | 0.050 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2023 | 472 | 0.050 |
Why?
|
| Fetal Blood | 1 | 2008 | 1317 | 0.050 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2023 | 595 | 0.050 |
Why?
|
| Prevalence | 2 | 2018 | 15194 | 0.040 |
Why?
|
| Vitamin D | 1 | 2013 | 3211 | 0.040 |
Why?
|
| Polyethylene Glycols | 2 | 2016 | 1181 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2018 | 15494 | 0.040 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2011 | 3381 | 0.040 |
Why?
|
| Cholesterol, LDL | 1 | 2008 | 2354 | 0.040 |
Why?
|
| Vaccination | 3 | 2014 | 3256 | 0.040 |
Why?
|
| Anti-Retroviral Agents | 1 | 2008 | 1712 | 0.040 |
Why?
|
| Interleukin-10 | 1 | 2023 | 1200 | 0.040 |
Why?
|
| Immunization, Passive | 1 | 2000 | 625 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2014 | 9941 | 0.040 |
Why?
|
| Recombinant Proteins | 3 | 2016 | 6608 | 0.040 |
Why?
|
| Lymphocyte Activation | 2 | 2016 | 5519 | 0.040 |
Why?
|
| Drug Therapy, Combination | 3 | 2013 | 6483 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2006 | 2485 | 0.040 |
Why?
|
| Ligands | 1 | 2023 | 3293 | 0.030 |
Why?
|
| United States | 4 | 2014 | 69693 | 0.030 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2000 | 657 | 0.030 |
Why?
|
| RNA, Viral | 3 | 2013 | 2899 | 0.030 |
Why?
|
| Child | 2 | 2022 | 77478 | 0.030 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2001 | 1320 | 0.030 |
Why?
|
| Young Adult | 5 | 2018 | 56350 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2008 | 9144 | 0.030 |
Why?
|
| HIV Antibodies | 1 | 2000 | 1320 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2006 | 6191 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 39004 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2023 | 3502 | 0.030 |
Why?
|
| Health Resources | 1 | 2018 | 911 | 0.030 |
Why?
|
| RNA | 1 | 2022 | 2747 | 0.030 |
Why?
|
| Squalene | 2 | 2001 | 32 | 0.030 |
Why?
|
| Polysorbates | 2 | 2001 | 41 | 0.030 |
Why?
|
| Immunity | 1 | 2017 | 1011 | 0.020 |
Why?
|
| Placebos | 1 | 2016 | 1677 | 0.020 |
Why?
|
| Double-Blind Method | 2 | 2016 | 12017 | 0.020 |
Why?
|
| Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2011 | 110 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2016 | 2030 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2018 | 3913 | 0.020 |
Why?
|
| Fatigue | 1 | 2017 | 1526 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2016 | 4438 | 0.020 |
Why?
|
| Pregnancy | 5 | 2017 | 29087 | 0.020 |
Why?
|
| Headache | 1 | 2017 | 1219 | 0.020 |
Why?
|
| Brazil | 1 | 2014 | 1263 | 0.020 |
Why?
|
| Models, Biological | 1 | 2006 | 9581 | 0.020 |
Why?
|
| Antigens, CD34 | 1 | 2011 | 657 | 0.020 |
Why?
|
| South Africa | 1 | 2014 | 1728 | 0.020 |
Why?
|
| Antibodies, Neutralizing | 1 | 2018 | 1970 | 0.020 |
Why?
|
| Adolescent | 5 | 2018 | 85649 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2006 | 12071 | 0.020 |
Why?
|
| Liver Cirrhosis | 1 | 2017 | 1864 | 0.020 |
Why?
|
| Cytochromes c | 1 | 2008 | 180 | 0.020 |
Why?
|
| Antigen-Presenting Cells | 1 | 2011 | 969 | 0.020 |
Why?
|
| Infant, Newborn | 5 | 2008 | 25575 | 0.020 |
Why?
|
| Prospective Studies | 3 | 2018 | 53187 | 0.020 |
Why?
|
| Apolipoprotein A-I | 1 | 2008 | 280 | 0.020 |
Why?
|
| Treatment Outcome | 4 | 2020 | 62966 | 0.020 |
Why?
|
| Biopsy | 1 | 2018 | 6756 | 0.020 |
Why?
|
| Apolipoproteins B | 1 | 2008 | 373 | 0.020 |
Why?
|
| Skin | 1 | 2018 | 4353 | 0.020 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2007 | 615 | 0.010 |
Why?
|
| Lipoprotein(a) | 1 | 2008 | 425 | 0.010 |
Why?
|
| Inflammation | 1 | 2023 | 10578 | 0.010 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2007 | 644 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2007 | 1653 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2007 | 1458 | 0.010 |
Why?
|
| Body Height | 1 | 2008 | 1574 | 0.010 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2001 | 370 | 0.010 |
Why?
|
| Vaccines, Subunit | 1 | 2001 | 168 | 0.010 |
Why?
|
| Cholesterol, HDL | 1 | 2008 | 1813 | 0.010 |
Why?
|
| Aged | 3 | 2017 | 162944 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2008 | 5180 | 0.010 |
Why?
|
| Triglycerides | 1 | 2008 | 2450 | 0.010 |
Why?
|
| HIV Core Protein p24 | 1 | 2000 | 256 | 0.010 |
Why?
|
| Birth Weight | 1 | 2008 | 2068 | 0.010 |
Why?
|
| Genotype | 1 | 2013 | 12946 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2008 | 6171 | 0.010 |
Why?
|
| Neutralization Tests | 1 | 2000 | 758 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 2000 | 792 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2007 | 6452 | 0.010 |
Why?
|
| Immunoglobulins | 1 | 2000 | 880 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2007 | 8436 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2018 | 40450 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2007 | 4414 | 0.010 |
Why?
|
| Immunization | 1 | 2000 | 1255 | 0.010 |
Why?
|
| Massachusetts | 1 | 2006 | 8662 | 0.010 |
Why?
|
| Comorbidity | 1 | 2007 | 10372 | 0.010 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2006 | 3014 | 0.010 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2000 | 1837 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2016 | 57683 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2006 | 15056 | 0.010 |
Why?
|
| Infant | 2 | 2001 | 35070 | 0.010 |
Why?
|
| Prognosis | 1 | 2006 | 29010 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 2000 | 19223 | 0.000 |
Why?
|
| Animals | 1 | 2013 | 168561 | 0.000 |
Why?
|
| Child, Preschool | 1 | 2000 | 40955 | 0.000 |
Why?
|
Concepts
(203)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(7)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_